AlphaCentric Life Sciences and Healthcare Fund C (LYFCX)
19.06
+0.21
(+1.11%)
USD |
Aug 25 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 2.41% | 50.64M | 0.52% | 107.0% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -2.241M | 54.60% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. The Fund invests in equity securities of companies in life sciences and healthcare sectors, which consists of companies related to producing facilities, supplies, technology, pharmaceuticals, equipment and services for the preservation and care of a persons health. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | AlphaCentric |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
32
-352.65M
Peer Group Low
875.64M
Peer Group High
1 Year
% Rank:
32
-2.241M
-2.135B
Peer Group Low
1.439B
Peer Group High
3 Months
% Rank:
36
-578.63M
Peer Group Low
875.49M
Peer Group High
3 Years
% Rank:
40
-7.321B
Peer Group Low
879.73M
Peer Group High
6 Months
% Rank:
20
-1.509B
Peer Group Low
884.06M
Peer Group High
5 Years
% Rank:
9
-8.821B
Peer Group Low
1.192B
Peer Group High
YTD
% Rank:
20
-1.022B
Peer Group Low
944.52M
Peer Group High
10 Years
% Rank:
--
-12.79B
Peer Group Low
5.576B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of August 26, 2026.
Asset Allocation
As of March 31, 2026.
| Type | % Net |
|---|---|
| Cash | 3.71% |
| Stock | 92.43% |
| Bond | 4.01% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | -0.15% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| First American Treasury Obligations Fund X | 7.72% | 1.00 | 0.00% |
| Gilead Sciences, Inc. | 7.18% | 147.78 | -0.67% |
| AstraZeneca PLC | 5.63% | 167.35 | -1.36% |
| Vertex Pharmaceuticals, Inc. | 5.60% | 548.74 | -0.74% |
| Ionis Pharmaceuticals, Inc. | 3.74% | 63.67 | 0.16% |
| Insmed, Inc. | 3.57% | 122.90 | -0.80% |
| Incyte Corp. | 3.41% | 128.62 | -0.85% |
| Roivant Sciences Ltd. | 3.36% | 36.62 | 0.41% |
| argenx SE | 3.33% | 1039.66 | 1.98% |
| Neurocrine Biosciences, Inc. | 3.22% | 153.75 | 0.25% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.58% |
| Administration Fee | 3309.00 None |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2500.00 None |
| Minimum Subsequent Investment | 100.00 None |
Projected Income
| Type | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of July 31, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. The Fund invests in equity securities of companies in life sciences and healthcare sectors, which consists of companies related to producing facilities, supplies, technology, pharmaceuticals, equipment and services for the preservation and care of a persons health. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | AlphaCentric |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (8-25-26) | 0.60% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 64 |
| Stock | |
| Weighted Average PE Ratio | 27.63 |
| Weighted Average Price to Sales Ratio | 16.95 |
| Weighted Average Price to Book Ratio | 9.043 |
| Weighted Median ROE | 110.9% |
| Weighted Median ROA | -9.50% |
| Return on Investment (TTM) | -13.16% |
| Earning Yield | 0.0413 |
| LT Debt / Shareholders Equity | 1.974 |
| Number of Equity Holdings | 62 |
As of March 31, 2026
Growth Metrics
| EPS Growth (1Y) | 27.85% |
| EPS Growth (3Y) | 22.65% |
| EPS Growth (5Y) | 20.69% |
| Sales Growth (1Y) | 23.15% |
| Sales Growth (3Y) | 24.77% |
| Sales Growth (5Y) | 21.19% |
| Sales per Share Growth (1Y) | 21.00% |
| Sales per Share Growth (3Y) | 21.95% |
| Operating Cash Flow - Growth Rate (3Y) | 8.83% |
As of March 31, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:LYFCX", "name") |
| Broad Asset Class: =YCI("M:LYFCX", "broad_asset_class") |
| Broad Category: =YCI("M:LYFCX", "broad_category_group") |
| Prospectus Objective: =YCI("M:LYFCX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |